中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
29期
8-9
,共2页
急性冠状动脉综合征%阿托伐他汀%心功能
急性冠狀動脈綜閤徵%阿託伐他汀%心功能
급성관상동맥종합정%아탁벌타정%심공능
Acute coronary syndyome%Atorvastatin%Cardiac function
目的:探讨强化阿托伐他汀治疗对急性冠状动脉综合征(ACS)患者心功能的影响。方法选择2012年1月至2012年12月在我院心内科住院确诊的ACS患者160例,将患者随机分为2组。分别为阿托伐他汀(辉瑞)20 mg/d常规治疗组及首剂80 mg负荷量,继之40 mg/d强化治疗组。所有实验对象在研究初始及2周后2次行肝功能、肌酸激酶、肾功能、血浆同型半胱氨酸(Hcy)、一氧化氮(nitric oxide,NO)浓度、血浆脑利钠肽(BNP)浓度测定。结果与常规治疗组比较,阿托伐他汀强化治疗组血浆Hcy、BNP水平明显降低,差异有统计学意义;两组治疗后NO水平明显升高,以强化治疗组升高更为显著,差异有统计学意义;无肝肾功能损伤、肌酸激酶明显升高等不良反应。结论对ACS患者来说,与20 mg/d阿托伐他汀比较,强化阿托伐他汀治疗可降低血浆同型半胱氨酸水平、改善患者心功能。
目的:探討彊化阿託伐他汀治療對急性冠狀動脈綜閤徵(ACS)患者心功能的影響。方法選擇2012年1月至2012年12月在我院心內科住院確診的ACS患者160例,將患者隨機分為2組。分彆為阿託伐他汀(輝瑞)20 mg/d常規治療組及首劑80 mg負荷量,繼之40 mg/d彊化治療組。所有實驗對象在研究初始及2週後2次行肝功能、肌痠激酶、腎功能、血漿同型半胱氨痠(Hcy)、一氧化氮(nitric oxide,NO)濃度、血漿腦利鈉肽(BNP)濃度測定。結果與常規治療組比較,阿託伐他汀彊化治療組血漿Hcy、BNP水平明顯降低,差異有統計學意義;兩組治療後NO水平明顯升高,以彊化治療組升高更為顯著,差異有統計學意義;無肝腎功能損傷、肌痠激酶明顯升高等不良反應。結論對ACS患者來說,與20 mg/d阿託伐他汀比較,彊化阿託伐他汀治療可降低血漿同型半胱氨痠水平、改善患者心功能。
목적:탐토강화아탁벌타정치료대급성관상동맥종합정(ACS)환자심공능적영향。방법선택2012년1월지2012년12월재아원심내과주원학진적ACS환자160례,장환자수궤분위2조。분별위아탁벌타정(휘서)20 mg/d상규치료조급수제80 mg부하량,계지40 mg/d강화치료조。소유실험대상재연구초시급2주후2차행간공능、기산격매、신공능、혈장동형반광안산(Hcy)、일양화담(nitric oxide,NO)농도、혈장뇌리납태(BNP)농도측정。결과여상규치료조비교,아탁벌타정강화치료조혈장Hcy、BNP수평명현강저,차이유통계학의의;량조치료후NO수평명현승고,이강화치료조승고경위현저,차이유통계학의의;무간신공능손상、기산격매명현승고등불량반응。결론대ACS환자래설,여20 mg/d아탁벌타정비교,강화아탁벌타정치료가강저혈장동형반광안산수평、개선환자심공능。
Objective To observe the effects of atorvastatin loading on cardiac function in patients with acute coronary syndyome (ACS). Methods Totally 160 patients with ACS in The iffth afifliated hospital of Zhengzhou University Cardiology from January 2012 to December 2012 were randomly divided into treatment group and control group. Treatment group were given a 80 mg loading dose, then atorvastatin 40 mg/d, control group were given atorvastatin 20 mg/d. Liver function, levels of serum creatine kinase (CK), renal function, plasma homocysteine (Hcy), nitric oxide (NO) and plasma brain natriuretic peptide (BNP) were measured before treatment and two weeks later. Results Levels of plasma Hcy and BNP in treatment group were signiifcantly lower than those in control group, the difference was statistically signiifcant;NO levels of the two groups improved signiifcantly, and treatment group increased more signiifcantly, the difference was statistically signiifcant;No liver and renal function damage, signiifcantly increased levels of serum CK were observed. Conclusions Atorvastatin loading given can reduce levels of plasma Hcy, improve ACS patients’ cardiac function.